{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:01:47Z","timestamp":1762480907787,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.gore.2020.100670","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T09:40:50Z","timestamp":1604310050000},"page":"100670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum"],"prefix":"10.1016","volume":"34","author":[{"given":"David M.","family":"Gershenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Bhosale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel N.","family":"Grisham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.gore.2020.100670_b0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.gore.2020.100670_b0010","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","article-title":"Low-grade serous ovarian cancer: state of the science","volume":"156","author":"Slomovitz","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2020.100670_b0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.gore.2020.100670_b0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: Binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","author":"Monk","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"suppl_5","key":"10.1016\/j.gore.2020.100670_b0025","first-page":"v851","article-title":"A randomized phase II\/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer","volume":"30","author":"Gershenson","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gore.2020.100670_b0030","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1200\/JCO.2015.62.4726","article-title":"Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer","volume":"33","author":"Grisham","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2020.100670_b0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40661-016-0026-5","article-title":"A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1\/2 inhibitor, selumetinib","volume":"3","author":"Takekuma","year":"2016","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"10.1016\/j.gore.2020.100670_b0040","first-page":"313","article-title":"Many ways to resistance: How melanoma cells evade targeted therapies","volume":"1871","author":"Kozar","year":"2019","journal-title":"Biochem. Biophys. Acta Rev. Can."},{"key":"10.1016\/j.gore.2020.100670_b0045","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1002\/ijc.24604","article-title":"Intrinsic resistance to MEK 1\/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK 1\/2 signaling and\/or strong PI3K signaling in colorectal cancer cell lines","volume":"125","author":"Balmanno","year":"2009","journal-title":"Int. J. Can."},{"key":"10.1016\/j.gore.2020.100670_b0050","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1158\/0008-5472.CAN-10-3647","article-title":"STAT3 mediates resistance to MEK inhibitor through microRNA miR-17","volume":"71","author":"Dai","year":"2011","journal-title":"Can. Res."},{"key":"10.1016\/j.gore.2020.100670_b0055","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/onc.2015.329","article-title":"Stamping out RAF and MEK 1\/2 to inhibit the ERK 1\/2 pathway: an emerging threat to anticancer therapy","volume":"35","author":"Mandal","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.gore.2020.100670_b0060","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1158\/0008-5472.CAN-14-1174","article-title":"Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy","volume":"74","author":"Kemper","year":"2014","journal-title":"Can. Res."},{"key":"10.1016\/j.gore.2020.100670_b0065","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.12.007","article-title":"Rechallenge with BRAF-directed treatment in metastatic melanoma: a multi-institutional retrospective study","volume":"91","author":"Valpione","year":"2018","journal-title":"Eur. J. Can."},{"issue":"10","key":"10.1016\/j.gore.2020.100670_b0070","first-page":"2235","article-title":"Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines","volume":"6","author":"Fernandez","year":"2016","journal-title":"Am. J. Can. Res."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578920301363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578920301363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:57:00Z","timestamp":1762480620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578920301363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":14,"alternative-id":["S2352578920301363"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2020.100670","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2020.100670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100670"}}